数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Barbara Duncan Director 53 5.16万(USD) 未持股 2018-04-23
Richard Murray Director,President and Chief Executive Officer 59 75.03万(USD) 未持股 2018-04-23
Cary G. Pfeffer Director 55 4.03万(USD) 未持股 2018-04-23
J. Duncan Higgons Director 63 5.02万(USD) 未持股 2018-04-23
Robert Kamen Director 73 3.38万(USD) 未持股 2018-04-23
Robert Tepper Director 62 3.21万(USD) 未持股 2018-04-23
Luis Diaz, Jr. Director 47 24.17万(USD) 未持股 2018-04-23
Perry A. Karsen Chairman and Director 62 8.13万(USD) 未持股 2018-04-23

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Richard Murray Director,President and Chief Executive Officer 59 75.03万(USD) 未持股 2018-04-23
Kim C. Drapkin Chief Financial Officer and Treasurer 50 87.52万(USD) 未持股 2018-04-23
Elizabeth G. Trehu Chief Medical Officer 57 51.36万(USD) 未持股 2018-04-23
Hugh M. Cole Chief Business Officer and Head of Corporate Development 53 217.47万(USD) 未持股 2018-04-23

董事简历

中英对照 |  中文 |  英文
Barbara Duncan

Barbara Duncan,她担任我们董事会的董事(2016年5月以来)。她曾担任Intercept Pharmaceuticals Inc.的首席财务官(2009年至2016年),以及财务主管(2010年至2016年)。2001年至2009年,她曾担任DOV Pharmaceutical, Inc的首席财务官,随后担任首席执行官。此前,她曾担任Lehman Brothers Inc.的公司财务部门的副总裁(1998年至2001年)。她任职于Adaptimmune Therapeutics plc、Medgenics, Inc的董事会,以及其它私人公司的董事会。她持有宾夕法尼亚大学的沃顿商学院(the Wharton School of the University of Pennsylvania)的工商管理硕士学位,以及Louisiana State University的学士学位。


Barbara Duncan has served as a member of our board of directors since December 2016. Ms. Duncan serves on the board of directors of Adaptimmune Therapeutics plc, Immunomedics, Inc., Jounce Therapeutics, Inc., and Ovid Therapeutics Inc., publicly traded biopharmaceutical companies. From November 2016 to April 2018 Ms. Duncan served as a member of the board of Innoviva Inc., and from July 2015 to February 2020 she served as member of the board of Aevi Genomic Medicine, Inc. From May 2009 through June 2016 Ms. Duncan served as the Chief Financial Officer of Intercept Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Intercept Pharmaceuticals, Inc., Ms. Duncan served as the Chief Financial Officer and then Chief Executive Officer of DOV Pharmaceutical, Inc. or DOV, from 2001 to April 2009. Prior to joining DOV, Ms. Duncan served as a vice president of Lehman Brothers Inc. in its corporate finance division from August 1998 to August 2001. From September 1994 to August 1998 Ms. Duncan was an associate and director at SBC Warburg Dillon Read, Inc. in its corporate finance group. Ms. Duncan received her B.S. from Louisiana State University, Baton Rouge, in 1985 and her M.B.A. from the Wharton School, University of Pennsylvania, Philadelphia, in 1994.
Barbara Duncan,她担任我们董事会的董事(2016年5月以来)。她曾担任Intercept Pharmaceuticals Inc.的首席财务官(2009年至2016年),以及财务主管(2010年至2016年)。2001年至2009年,她曾担任DOV Pharmaceutical, Inc的首席财务官,随后担任首席执行官。此前,她曾担任Lehman Brothers Inc.的公司财务部门的副总裁(1998年至2001年)。她任职于Adaptimmune Therapeutics plc、Medgenics, Inc的董事会,以及其它私人公司的董事会。她持有宾夕法尼亚大学的沃顿商学院(the Wharton School of the University of Pennsylvania)的工商管理硕士学位,以及Louisiana State University的学士学位。
Barbara Duncan has served as a member of our board of directors since December 2016. Ms. Duncan serves on the board of directors of Adaptimmune Therapeutics plc, Immunomedics, Inc., Jounce Therapeutics, Inc., and Ovid Therapeutics Inc., publicly traded biopharmaceutical companies. From November 2016 to April 2018 Ms. Duncan served as a member of the board of Innoviva Inc., and from July 2015 to February 2020 she served as member of the board of Aevi Genomic Medicine, Inc. From May 2009 through June 2016 Ms. Duncan served as the Chief Financial Officer of Intercept Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Intercept Pharmaceuticals, Inc., Ms. Duncan served as the Chief Financial Officer and then Chief Executive Officer of DOV Pharmaceutical, Inc. or DOV, from 2001 to April 2009. Prior to joining DOV, Ms. Duncan served as a vice president of Lehman Brothers Inc. in its corporate finance division from August 1998 to August 2001. From September 1994 to August 1998 Ms. Duncan was an associate and director at SBC Warburg Dillon Read, Inc. in its corporate finance group. Ms. Duncan received her B.S. from Louisiana State University, Baton Rouge, in 1985 and her M.B.A. from the Wharton School, University of Pennsylvania, Philadelphia, in 1994.
Richard Murray

Richard Murray,他曾一直担任我们的总裁、首席执行官,以及我们董事会的董事(2014年7月以来)。加入Jounce之前,他曾担任Merck & Co.的高级副总裁,负责生物制剂和疫苗研发(2009年至2014年),在那里他负责提供生物制剂和疫苗,包括默克的癌症免疫疗法。2008年至2009年,他曾担任风险资本和生命科学投资者的顾问。2003年至2008年,他曾担任PDL Biopharma Inc.(PDL)的多种职务,最初担任研究副总裁,后担任执行副总裁兼首席科学官。他也曾担任PDL公司的董事(从2007年到2008年)。职业生涯早期,他曾担任Eos Biotechnology, Inc的联席创始人,也曾担任研究副总裁(1998年至2003年)。他持有the University of North Carolina at Chapel Hill的微生物学和免疫学的博士学位,以及马萨诸塞大学(the University of Massachusetts,位于阿默斯特)的微生物学学士学位。


Richard Murray, Ph.D.,Dr. Murray has served as our president, chief executive officer and a member of our board of directors since July 2014. Prior to joining Jounce, Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co., a global healthcare company, from 2009 to June 2014 where he was responsible for the advancement of biologics and vaccines, including Merck's cancer immunotherapy pipeline. From 2008 to 2009 Dr. Murray served as an advisor to venture capital and life science investors. From 2003 to 2008 he served in a variety of roles at PDL Biopharma Inc., or PDL, initially as vice president of research to executive vice president and chief scientific officer. He also served as a director of PDL from 2007 to 2008. Earlier in his career, Dr. Murray was a co-founder and served as vice president of research at Eos Biotechnology, Inc. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.
Richard Murray,他曾一直担任我们的总裁、首席执行官,以及我们董事会的董事(2014年7月以来)。加入Jounce之前,他曾担任Merck & Co.的高级副总裁,负责生物制剂和疫苗研发(2009年至2014年),在那里他负责提供生物制剂和疫苗,包括默克的癌症免疫疗法。2008年至2009年,他曾担任风险资本和生命科学投资者的顾问。2003年至2008年,他曾担任PDL Biopharma Inc.(PDL)的多种职务,最初担任研究副总裁,后担任执行副总裁兼首席科学官。他也曾担任PDL公司的董事(从2007年到2008年)。职业生涯早期,他曾担任Eos Biotechnology, Inc的联席创始人,也曾担任研究副总裁(1998年至2003年)。他持有the University of North Carolina at Chapel Hill的微生物学和免疫学的博士学位,以及马萨诸塞大学(the University of Massachusetts,位于阿默斯特)的微生物学学士学位。
Richard Murray, Ph.D.,Dr. Murray has served as our president, chief executive officer and a member of our board of directors since July 2014. Prior to joining Jounce, Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co., a global healthcare company, from 2009 to June 2014 where he was responsible for the advancement of biologics and vaccines, including Merck's cancer immunotherapy pipeline. From 2008 to 2009 Dr. Murray served as an advisor to venture capital and life science investors. From 2003 to 2008 he served in a variety of roles at PDL Biopharma Inc., or PDL, initially as vice president of research to executive vice president and chief scientific officer. He also served as a director of PDL from 2007 to 2008. Earlier in his career, Dr. Murray was a co-founder and served as vice president of research at Eos Biotechnology, Inc. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.
Cary G. Pfeffer

Cary G. Pfeffer,他担任我们董事会的董事(2013年2月以来)。此前,他曾担任我们的董事会主席(从2014年到2016年),以及我们的临时首席执行官(从2013年到2014年)。他是Third Rock Ventures, LLC(于2007年加入该公司)的合伙人。从2015年到2016年,他担任Neon Therapeutics, Inc.的临时首席执行官。他曾任职Biogen Inc.(1992年至2002年),担任多种国内和国际执行管理职务。他任职于Ablexis, LLC、Edimer Pharmaceuticals, Inc.、Neon Therapeutics, Inc的董事会,在那里他担任董事会主席。他获得the Wharton School的工商管理硕士学位、the University of Pennsylvania School of Medicine的医学博士学位,以及哥伦比亚大学(Columbia University)的生物化学学士学位。


Cary G. Pfeffer, M.D.,Dr. Pfeffer is the interim chief business officer of Rheos Medicines, Inc., a biopharmaceutical company, which he joined in March 2018 and is a partner at Third Rock Ventures, LLC, which he joined in 2007. Dr. Pfeffer served as the chairman of our board from July 2014 to April 2016 and as our interim chief executive officer from February 2013 to July 2014. Dr. Pfeffer was the interim chief executive officer of Neon Therapeutics, Inc. from October 2015 to September 2016. Dr. Pfeffer served at Biogen Inc. from 1992 to 2002 in a variety of domestic and international executive management roles. Dr. Pfeffer serves on the boards of directors for several private companies, including Ablexis, LLC, Edimer Pharmaceuticals, Inc., Tango Therapeutics, Inc. and Neon Therapeutics, Inc., where he serves as chairman of the board. From August 2009 to September 2016 Dr. Pfeffer was a member of the board of directors of Eleven Biotherapeutics, Inc., a public biologics oncology company, and served as its chief business officer from February 2010 to September 2011. Dr. Pfeffer received an M.B.A. from the Wharton School of Business, an M.D. from the University of Pennsylvania School of Medicine and a B.A. in biochemistry from Columbia University.
Cary G. Pfeffer,他担任我们董事会的董事(2013年2月以来)。此前,他曾担任我们的董事会主席(从2014年到2016年),以及我们的临时首席执行官(从2013年到2014年)。他是Third Rock Ventures, LLC(于2007年加入该公司)的合伙人。从2015年到2016年,他担任Neon Therapeutics, Inc.的临时首席执行官。他曾任职Biogen Inc.(1992年至2002年),担任多种国内和国际执行管理职务。他任职于Ablexis, LLC、Edimer Pharmaceuticals, Inc.、Neon Therapeutics, Inc的董事会,在那里他担任董事会主席。他获得the Wharton School的工商管理硕士学位、the University of Pennsylvania School of Medicine的医学博士学位,以及哥伦比亚大学(Columbia University)的生物化学学士学位。
Cary G. Pfeffer, M.D.,Dr. Pfeffer is the interim chief business officer of Rheos Medicines, Inc., a biopharmaceutical company, which he joined in March 2018 and is a partner at Third Rock Ventures, LLC, which he joined in 2007. Dr. Pfeffer served as the chairman of our board from July 2014 to April 2016 and as our interim chief executive officer from February 2013 to July 2014. Dr. Pfeffer was the interim chief executive officer of Neon Therapeutics, Inc. from October 2015 to September 2016. Dr. Pfeffer served at Biogen Inc. from 1992 to 2002 in a variety of domestic and international executive management roles. Dr. Pfeffer serves on the boards of directors for several private companies, including Ablexis, LLC, Edimer Pharmaceuticals, Inc., Tango Therapeutics, Inc. and Neon Therapeutics, Inc., where he serves as chairman of the board. From August 2009 to September 2016 Dr. Pfeffer was a member of the board of directors of Eleven Biotherapeutics, Inc., a public biologics oncology company, and served as its chief business officer from February 2010 to September 2011. Dr. Pfeffer received an M.B.A. from the Wharton School of Business, an M.D. from the University of Pennsylvania School of Medicine and a B.A. in biochemistry from Columbia University.
J. Duncan Higgons
暂无中文简介

J. Duncan Higgons,Mr. Higgons served as chief operating officer of Agios Therapeutics, Inc., or Agios, a public biopharmaceutical company, from 2009 to January 2016. Prior to joining Agios, Mr. Higgons served as executive vice-president, and interim president and chief executive officer at Archemix Corporation, or Archemix, from 2006 to 2009. Prior to Archemix, Mr. Higgons served as the chief commercial officer at TransForm Pharmaceuticals, Inc., which was acquired by Johnson & Johnson Company. Mr. Higgons serves on the board of PsiOxus Therapeutics Ltd., a private cancer therapeutics company. He holds a B.Sc. in Mathematics from King's College University of London and a M.Sc. in Economics from London Business School.
暂无中文简介
J. Duncan Higgons,Mr. Higgons served as chief operating officer of Agios Therapeutics, Inc., or Agios, a public biopharmaceutical company, from 2009 to January 2016. Prior to joining Agios, Mr. Higgons served as executive vice-president, and interim president and chief executive officer at Archemix Corporation, or Archemix, from 2006 to 2009. Prior to Archemix, Mr. Higgons served as the chief commercial officer at TransForm Pharmaceuticals, Inc., which was acquired by Johnson & Johnson Company. Mr. Higgons serves on the board of PsiOxus Therapeutics Ltd., a private cancer therapeutics company. He holds a B.Sc. in Mathematics from King's College University of London and a M.Sc. in Economics from London Business School.
Robert Kamen

Robert Kamen,他担任我们的董事会成员(2013年6月以来)。他也曾担任我们的临时首席技术官(从2013年到2015年)。他是Third Rock Ventures, LLC(于2010年加入该公司)的驻企高管。从2005年到2010年,他担任BioAssets Development Corporation的董事长。从2002年到2008年,他担任Oxford Bioscience Partners的驻企高管。2001年至2002年,他曾担任Abbot Laboratories'' Abbot Bioresearch Center的总裁,以及Abbot Pharma的执行管理委员会的成员。从1991年到2001年,他担任BASF Bioresearch Corporation的总裁。他任职于多个公司的董事会,包括BioAssets Development Corporation, Inc.、EpimAb Biotherapeutics, Inc.、Harbour Antibodies BV、Lycera Corporation、Opsonic Therapeutics Inc.、Neon Therapeutics, Inc.。他持有Harvard University的生物化学与分子生物学博士学位,以及Amherst College的生物物理学学士学位。


Robert Kamen, Ph.D.,Dr. Kamen is a venture partner at Third Rock Ventures, LLC, which he joined in 2010. Dr. Kamen served as our interim chief technology officer from February 2013 to December 2015. From 2005 to 2010 Dr. Kamen served as the chairman of BioAssets Development Corporation. From 2002 to 2008 Dr. Kamen served as executive-in-residence at Oxford Bioscience Partners. From 2001 to 2002 he served as president of Abbott Laboratories' Abbot Bioresearch Center and as a member of the Abbott Pharma Executive Management Committee, and from 1991 to 2001 he served as the president of BASF Bioresearch Corporation. Dr. Kamen serves on the boards of directors for numerous private companies, including EpimAb Biotherapeutics, Inc., Harbour Antibodies BV, Lycera Corporation and Neon Therapeutics, Inc. Dr. Kamen holds a Ph.D. in biochemistry and molecular biology from Harvard University and a B.S. in biophysics from Amherst College.
Robert Kamen,他担任我们的董事会成员(2013年6月以来)。他也曾担任我们的临时首席技术官(从2013年到2015年)。他是Third Rock Ventures, LLC(于2010年加入该公司)的驻企高管。从2005年到2010年,他担任BioAssets Development Corporation的董事长。从2002年到2008年,他担任Oxford Bioscience Partners的驻企高管。2001年至2002年,他曾担任Abbot Laboratories'' Abbot Bioresearch Center的总裁,以及Abbot Pharma的执行管理委员会的成员。从1991年到2001年,他担任BASF Bioresearch Corporation的总裁。他任职于多个公司的董事会,包括BioAssets Development Corporation, Inc.、EpimAb Biotherapeutics, Inc.、Harbour Antibodies BV、Lycera Corporation、Opsonic Therapeutics Inc.、Neon Therapeutics, Inc.。他持有Harvard University的生物化学与分子生物学博士学位,以及Amherst College的生物物理学学士学位。
Robert Kamen, Ph.D.,Dr. Kamen is a venture partner at Third Rock Ventures, LLC, which he joined in 2010. Dr. Kamen served as our interim chief technology officer from February 2013 to December 2015. From 2005 to 2010 Dr. Kamen served as the chairman of BioAssets Development Corporation. From 2002 to 2008 Dr. Kamen served as executive-in-residence at Oxford Bioscience Partners. From 2001 to 2002 he served as president of Abbott Laboratories' Abbot Bioresearch Center and as a member of the Abbott Pharma Executive Management Committee, and from 1991 to 2001 he served as the president of BASF Bioresearch Corporation. Dr. Kamen serves on the boards of directors for numerous private companies, including EpimAb Biotherapeutics, Inc., Harbour Antibodies BV, Lycera Corporation and Neon Therapeutics, Inc. Dr. Kamen holds a Ph.D. in biochemistry and molecular biology from Harvard University and a B.S. in biophysics from Amherst College.
Robert Tepper
暂无中文简介

Robert Tepper, M.D.,Since 2007 Dr. Tepper has served as a partner at Third Rock Ventures, LLC, a venture capital fund, which he co-founded in 2007. From February 2013 to January 2015 Dr. Tepper served as our interim chief scientific officer and, from October 2015 to November 2016 he served as the interim chief scientific officer of Neon Therapeutics, Inc., an immuno-oncology company. Prior to joining Third Rock Ventures, LLC, Dr. Tepper held multiple positions at Millennium Pharmaceuticals, Inc., including as president of research and development from 2002 to 2007 executive vice president of discovery from 2001 to 2002 and chief scientific officer from 1999 to 2002. Dr. Tepper serves on the boards of directors for numerous companies, including publicly-traded companies Allena Pharmaceuticals, Inc. and Kala Pharmaceuticals, Inc., and private companies Constellation Pharmaceuticals, Inc. and Neon Therapeutics, Inc. Previously, Dr. Tepper served on the board of directors of Bluebird Bio, Inc. from September 2010 through March 2015 and various other private life science companies. Dr. Tepper received an M.D. from Harvard Medical School and an A.B. in biochemistry from Princeton University.
暂无中文简介
Robert Tepper, M.D.,Since 2007 Dr. Tepper has served as a partner at Third Rock Ventures, LLC, a venture capital fund, which he co-founded in 2007. From February 2013 to January 2015 Dr. Tepper served as our interim chief scientific officer and, from October 2015 to November 2016 he served as the interim chief scientific officer of Neon Therapeutics, Inc., an immuno-oncology company. Prior to joining Third Rock Ventures, LLC, Dr. Tepper held multiple positions at Millennium Pharmaceuticals, Inc., including as president of research and development from 2002 to 2007 executive vice president of discovery from 2001 to 2002 and chief scientific officer from 1999 to 2002. Dr. Tepper serves on the boards of directors for numerous companies, including publicly-traded companies Allena Pharmaceuticals, Inc. and Kala Pharmaceuticals, Inc., and private companies Constellation Pharmaceuticals, Inc. and Neon Therapeutics, Inc. Previously, Dr. Tepper served on the board of directors of Bluebird Bio, Inc. from September 2010 through March 2015 and various other private life science companies. Dr. Tepper received an M.D. from Harvard Medical School and an A.B. in biochemistry from Princeton University.
Luis Diaz, Jr.
暂无中文简介

Luis Diaz, Jr., M.D.,Dr. Diaz has served as the head of the solid tumor oncology division and a faculty member at the Memorial Sloan Kettering Cancer Center since December 2016. From 2004 to December 2016 Dr. Diaz was a faculty member and physician at Johns Hopkins University School of Medicine. Dr. Diaz is also a founder and board member, and from 2010 to April 2016 served as president, chief executive officer and chief medical officer, of Personal Genome Diagnostics Inc., a private cancer genome analysis company. He received his M.D. from the University of Michigan, where he also received his B.A. in Microbiology.
暂无中文简介
Luis Diaz, Jr., M.D.,Dr. Diaz has served as the head of the solid tumor oncology division and a faculty member at the Memorial Sloan Kettering Cancer Center since December 2016. From 2004 to December 2016 Dr. Diaz was a faculty member and physician at Johns Hopkins University School of Medicine. Dr. Diaz is also a founder and board member, and from 2010 to April 2016 served as president, chief executive officer and chief medical officer, of Personal Genome Diagnostics Inc., a private cancer genome analysis company. He received his M.D. from the University of Michigan, where he also received his B.A. in Microbiology.
Perry A. Karsen

Perry A. Karsen自2010年7月起担任首席营运官。他于2012年2月15日担任执行副总裁兼首席营运官。 他对所有营运操作负责,包括信息技术、企业和业务发展、技术操作和细胞治疗单位。 从2009年2月至2010年7月,他曾担任明珠治疗(一家私有的生物科技公司)的总裁兼首席执行官。从2004年到2009年,他担任高级副总裁兼全球业务发展部的总监,以总裁的身份负责亚太地区的新兴业务。在这之前,他曾在人类基因组科学Bristol-Myers-Squibb, Genentech and Abbott实验室担任行政职务。此外, 他还担任Pequot企业的普通合伙人。他是生物技术工业组织BIO的董事会成员;BayBio的董事会成员;生命科学基金会的董事会成员。另外,他还是Agios配药公司(一家私有的生物科技公司)的董事会成员。他在西北大学的凯洛格管理研究生院获得管理学学位, 在杜克大学获得生物学教学硕士学位,在伊利诺伊州厄巴纳大学获得生物科学学士学位。


Perry A. Karsen has served as a director on our board of directors since January 2016 and as Executive Chairman of the board of directors since January 2018. Mr. Karsen was the Chief Executive Officer of Celgene Cellular Therapeutics from May 2013 until his retirement from Celgene Corporation at the end of 2015. Mr. Karsen held the position of Executive Vice President and Chief Operations Officer at Celgene Corporation from July 2010 to May 2013 and he served as Senior Vice President and Head of Worldwide Business Development at Celgene and President of Asia/Pacific Region, from May 2004 until February 2009. Mr. Karsen was the President and Chief Executive Officer of Pearl Therapeutics, a privately held biotechnology company subsequently acquired by AstraZeneca, from February 2009 until July 2010. In addition, Mr. Karsen held executive positions at Human Genome Sciences, Bristol-Myers Squibb, Genentech and Abbott Laboratories earlier in his career. He also was a General Partner at Pequot Ventures from 2000 to 2003 focusing on investments in biotechnology and medical devices. Mr. Karsen currently serves on the Board of Directors of Agios Pharmaceuticals, Alliqua Biomedical, Jounce Therapeutics, and Voyager Therapeutics, as well as The Gladstone Foundation and The Sonoma Land Trust. He is a past member of the Board of Directors and the Executive Committee of the Biotechnology Industry Organization BIO and the Board of Directors of the Alliance for Regenerative Medicine (ARM). Mr. Karsen received a B.S. in Biological Sciences from the University of Illinois, Urbana, a Master of Arts in Teaching Biology from Duke University, and an MBA from the Kellogg School of Management at Northwestern University.
Perry A. Karsen自2010年7月起担任首席营运官。他于2012年2月15日担任执行副总裁兼首席营运官。 他对所有营运操作负责,包括信息技术、企业和业务发展、技术操作和细胞治疗单位。 从2009年2月至2010年7月,他曾担任明珠治疗(一家私有的生物科技公司)的总裁兼首席执行官。从2004年到2009年,他担任高级副总裁兼全球业务发展部的总监,以总裁的身份负责亚太地区的新兴业务。在这之前,他曾在人类基因组科学Bristol-Myers-Squibb, Genentech and Abbott实验室担任行政职务。此外, 他还担任Pequot企业的普通合伙人。他是生物技术工业组织BIO的董事会成员;BayBio的董事会成员;生命科学基金会的董事会成员。另外,他还是Agios配药公司(一家私有的生物科技公司)的董事会成员。他在西北大学的凯洛格管理研究生院获得管理学学位, 在杜克大学获得生物学教学硕士学位,在伊利诺伊州厄巴纳大学获得生物科学学士学位。
Perry A. Karsen has served as a director on our board of directors since January 2016 and as Executive Chairman of the board of directors since January 2018. Mr. Karsen was the Chief Executive Officer of Celgene Cellular Therapeutics from May 2013 until his retirement from Celgene Corporation at the end of 2015. Mr. Karsen held the position of Executive Vice President and Chief Operations Officer at Celgene Corporation from July 2010 to May 2013 and he served as Senior Vice President and Head of Worldwide Business Development at Celgene and President of Asia/Pacific Region, from May 2004 until February 2009. Mr. Karsen was the President and Chief Executive Officer of Pearl Therapeutics, a privately held biotechnology company subsequently acquired by AstraZeneca, from February 2009 until July 2010. In addition, Mr. Karsen held executive positions at Human Genome Sciences, Bristol-Myers Squibb, Genentech and Abbott Laboratories earlier in his career. He also was a General Partner at Pequot Ventures from 2000 to 2003 focusing on investments in biotechnology and medical devices. Mr. Karsen currently serves on the Board of Directors of Agios Pharmaceuticals, Alliqua Biomedical, Jounce Therapeutics, and Voyager Therapeutics, as well as The Gladstone Foundation and The Sonoma Land Trust. He is a past member of the Board of Directors and the Executive Committee of the Biotechnology Industry Organization BIO and the Board of Directors of the Alliance for Regenerative Medicine (ARM). Mr. Karsen received a B.S. in Biological Sciences from the University of Illinois, Urbana, a Master of Arts in Teaching Biology from Duke University, and an MBA from the Kellogg School of Management at Northwestern University.

高管简历

中英对照 |  中文 |  英文
Richard Murray

Richard Murray,他曾一直担任我们的总裁、首席执行官,以及我们董事会的董事(2014年7月以来)。加入Jounce之前,他曾担任Merck & Co.的高级副总裁,负责生物制剂和疫苗研发(2009年至2014年),在那里他负责提供生物制剂和疫苗,包括默克的癌症免疫疗法。2008年至2009年,他曾担任风险资本和生命科学投资者的顾问。2003年至2008年,他曾担任PDL Biopharma Inc.(PDL)的多种职务,最初担任研究副总裁,后担任执行副总裁兼首席科学官。他也曾担任PDL公司的董事(从2007年到2008年)。职业生涯早期,他曾担任Eos Biotechnology, Inc的联席创始人,也曾担任研究副总裁(1998年至2003年)。他持有the University of North Carolina at Chapel Hill的微生物学和免疫学的博士学位,以及马萨诸塞大学(the University of Massachusetts,位于阿默斯特)的微生物学学士学位。


Richard Murray, Ph.D.,Dr. Murray has served as our president, chief executive officer and a member of our board of directors since July 2014. Prior to joining Jounce, Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co., a global healthcare company, from 2009 to June 2014 where he was responsible for the advancement of biologics and vaccines, including Merck's cancer immunotherapy pipeline. From 2008 to 2009 Dr. Murray served as an advisor to venture capital and life science investors. From 2003 to 2008 he served in a variety of roles at PDL Biopharma Inc., or PDL, initially as vice president of research to executive vice president and chief scientific officer. He also served as a director of PDL from 2007 to 2008. Earlier in his career, Dr. Murray was a co-founder and served as vice president of research at Eos Biotechnology, Inc. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.
Richard Murray,他曾一直担任我们的总裁、首席执行官,以及我们董事会的董事(2014年7月以来)。加入Jounce之前,他曾担任Merck & Co.的高级副总裁,负责生物制剂和疫苗研发(2009年至2014年),在那里他负责提供生物制剂和疫苗,包括默克的癌症免疫疗法。2008年至2009年,他曾担任风险资本和生命科学投资者的顾问。2003年至2008年,他曾担任PDL Biopharma Inc.(PDL)的多种职务,最初担任研究副总裁,后担任执行副总裁兼首席科学官。他也曾担任PDL公司的董事(从2007年到2008年)。职业生涯早期,他曾担任Eos Biotechnology, Inc的联席创始人,也曾担任研究副总裁(1998年至2003年)。他持有the University of North Carolina at Chapel Hill的微生物学和免疫学的博士学位,以及马萨诸塞大学(the University of Massachusetts,位于阿默斯特)的微生物学学士学位。
Richard Murray, Ph.D.,Dr. Murray has served as our president, chief executive officer and a member of our board of directors since July 2014. Prior to joining Jounce, Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co., a global healthcare company, from 2009 to June 2014 where he was responsible for the advancement of biologics and vaccines, including Merck's cancer immunotherapy pipeline. From 2008 to 2009 Dr. Murray served as an advisor to venture capital and life science investors. From 2003 to 2008 he served in a variety of roles at PDL Biopharma Inc., or PDL, initially as vice president of research to executive vice president and chief scientific officer. He also served as a director of PDL from 2007 to 2008. Earlier in his career, Dr. Murray was a co-founder and served as vice president of research at Eos Biotechnology, Inc. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.
Kim C. Drapkin

Kim C. Drapkin,她曾担任我们的首席财务官(2015年8月以来),以及我们的财务主管(2013年2月以来)。从2009年到2015年,她曾担任KCD Financial LLC的所有者,也曾担任我们的临时首席财务官(2012年至2015年8月),并负责许多生物技术公司的咨询。此前,她曾担任Predix Pharmaceuticals holdings, Inc.(Predix)的首席财务官(2005年至2006年)。此前,Predix公司被EPIX Pharmaceuticals, Inc(EPIX)收购。她曾担任EPIX的首席财务官(2006年至2009年)。职业生涯中(1995年至2005年),她曾担任Millennium Pharmaceuticals, Inc.的多种职务,包括财务主管。她的职业生涯始于任职PricewaterhouseCoopers LLP,并获得Babson College的会计学士学位。


Kim C. Drapkin,Ms. Drapkin has served as our chief financial officer since August 2015 and our treasurer since February 2013. From 2009 to August 2015 Ms. Drapkin was the owner of KCD Financial LLC, through which she served as our interim chief financial officer from 2012 to August 2015 and consulted for numerous biotechnology companies. Previously, Ms. Drapkin served as the chief financial officer of Predix Pharmaceuticals Holdings, Inc. from 2005 to 2006 and, after Predix was acquired by EPIX Pharmaceuticals, Inc., as chief financial officer of EPIX from 2006 to 2009. From 1995 to 2005 Ms. Drapkin served in a variety of roles at Millennium Pharmaceuticals, Inc., including director of finance. Ms. Drapkin began her career at PricewaterhouseCoopers LLP, is a certified public accountant and holds a B.S. in accounting from Babson College.
Kim C. Drapkin,她曾担任我们的首席财务官(2015年8月以来),以及我们的财务主管(2013年2月以来)。从2009年到2015年,她曾担任KCD Financial LLC的所有者,也曾担任我们的临时首席财务官(2012年至2015年8月),并负责许多生物技术公司的咨询。此前,她曾担任Predix Pharmaceuticals holdings, Inc.(Predix)的首席财务官(2005年至2006年)。此前,Predix公司被EPIX Pharmaceuticals, Inc(EPIX)收购。她曾担任EPIX的首席财务官(2006年至2009年)。职业生涯中(1995年至2005年),她曾担任Millennium Pharmaceuticals, Inc.的多种职务,包括财务主管。她的职业生涯始于任职PricewaterhouseCoopers LLP,并获得Babson College的会计学士学位。
Kim C. Drapkin,Ms. Drapkin has served as our chief financial officer since August 2015 and our treasurer since February 2013. From 2009 to August 2015 Ms. Drapkin was the owner of KCD Financial LLC, through which she served as our interim chief financial officer from 2012 to August 2015 and consulted for numerous biotechnology companies. Previously, Ms. Drapkin served as the chief financial officer of Predix Pharmaceuticals Holdings, Inc. from 2005 to 2006 and, after Predix was acquired by EPIX Pharmaceuticals, Inc., as chief financial officer of EPIX from 2006 to 2009. From 1995 to 2005 Ms. Drapkin served in a variety of roles at Millennium Pharmaceuticals, Inc., including director of finance. Ms. Drapkin began her career at PricewaterhouseCoopers LLP, is a certified public accountant and holds a B.S. in accounting from Babson College.
Elizabeth G. Trehu

Elizabeth G. Trehu,她于2015年11月加入我们公司,担任我们的首席医疗官。加入Jounce公司之前,她曾担任Promedior, Inc的首席医疗官(从2012年到2015年)。此前,她曾担任Infinity Pharmaceuticals, Inc.的副总裁,负责产品开发和医疗事务(2010年至2012年)。职业生涯早期,她曾担任Genzyme Corporation的多种职务,包括担任副总裁兼总经理,负责血液学(从2009年到2010年)、副总裁兼总经理,负责氯法拉滨(Clolar)(2008年至2009年)、副总裁,负责Genzyme Oncology的全球医疗事务(2006年至2008年)。此前,她曾担任Millennium Pharmaceuticals, Inc的多种职务(2002年至2006年),并于2006年担任副总裁,负责肿瘤全球医疗事务。她持有the New York University School of Medicine的医学博士学位,以及Princeton University的英语学士学位。


Elizabeth G. Trehu, M.D.,Dr. Trehu joined Jounce as our chief medical officer in November 2015. Prior to joining Jounce, Dr. Trehu served as the chief medical officer of Promedior, Inc., a biotechnology company, from 2012 to November 2015. Previously, Dr. Trehu served as vice president, product development and medical affairs for Infinity Pharmaceuticals, Inc. from 2010 to 2012. Earlier in her career, Dr. Trehu served in a variety of roles for Genzyme Corporation, including as the vice president and general manager, hematology from 2009 to 2010 vice president and general manager of Clolar from 2008 to 2009 and vice president, global medical affairs of Genzyme Oncology from 2006 to 2008. Earlier in her career, Dr. Trehu served from 2002 to 2006 in a variety of positions at Millennium Pharmaceuticals, Inc., including as vice president of oncology global medical affairs in 2006. Dr. Trehu holds an M.D. from the New York University School of Medicine and an A.B. in English from Princeton University.
Elizabeth G. Trehu,她于2015年11月加入我们公司,担任我们的首席医疗官。加入Jounce公司之前,她曾担任Promedior, Inc的首席医疗官(从2012年到2015年)。此前,她曾担任Infinity Pharmaceuticals, Inc.的副总裁,负责产品开发和医疗事务(2010年至2012年)。职业生涯早期,她曾担任Genzyme Corporation的多种职务,包括担任副总裁兼总经理,负责血液学(从2009年到2010年)、副总裁兼总经理,负责氯法拉滨(Clolar)(2008年至2009年)、副总裁,负责Genzyme Oncology的全球医疗事务(2006年至2008年)。此前,她曾担任Millennium Pharmaceuticals, Inc的多种职务(2002年至2006年),并于2006年担任副总裁,负责肿瘤全球医疗事务。她持有the New York University School of Medicine的医学博士学位,以及Princeton University的英语学士学位。
Elizabeth G. Trehu, M.D.,Dr. Trehu joined Jounce as our chief medical officer in November 2015. Prior to joining Jounce, Dr. Trehu served as the chief medical officer of Promedior, Inc., a biotechnology company, from 2012 to November 2015. Previously, Dr. Trehu served as vice president, product development and medical affairs for Infinity Pharmaceuticals, Inc. from 2010 to 2012. Earlier in her career, Dr. Trehu served in a variety of roles for Genzyme Corporation, including as the vice president and general manager, hematology from 2009 to 2010 vice president and general manager of Clolar from 2008 to 2009 and vice president, global medical affairs of Genzyme Oncology from 2006 to 2008. Earlier in her career, Dr. Trehu served from 2002 to 2006 in a variety of positions at Millennium Pharmaceuticals, Inc., including as vice president of oncology global medical affairs in 2006. Dr. Trehu holds an M.D. from the New York University School of Medicine and an A.B. in English from Princeton University.
Hugh M. Cole

2014年3月以来,Hugh M. Cole曾担任我们的高级副总裁兼首席商务官。从2007年到2014年,他在夏尔制药担任管理职位,最近成为了高级副总裁,主要负责战略规划和项目管理。在这支前,他是一个全球特许经营人员,,再之前,,他还担任过业务发展副总裁。此前,他还在Oscient Pharmaceuticals、Genome Therapeutics、 Millennium Pharmaceuticals 及其子公司担任过高级职位。


Hugh M. Cole,Prior to joining Jounce in August 2017 Mr. Cole served as chief business officer for ARIAD Pharmaceuticals, Inc., an oncology company, from March 2014 to June 2017 where he led numerous business development transactions. Previously, Mr. Cole served as senior vice president, strategic planning and program management at Shire plc, a global biopharmaceutical company, from 2007 to March 2014. At Shire, Mr. Cole's responsibilities included the global development strategy and commercialization of the rare disease drug Firazyr. Earlier in his career, Mr. Cole was vice president, corporate development for Oscient Pharmaceuticals, Inc. and served as senior director, business development and strategy at Millennium Pharmaceuticals, Inc. Mr. Cole earned his M.B.A. in health care management and finance at the Wharton School of Business and his A.B. in chemistry from Harvard University.
2014年3月以来,Hugh M. Cole曾担任我们的高级副总裁兼首席商务官。从2007年到2014年,他在夏尔制药担任管理职位,最近成为了高级副总裁,主要负责战略规划和项目管理。在这支前,他是一个全球特许经营人员,,再之前,,他还担任过业务发展副总裁。此前,他还在Oscient Pharmaceuticals、Genome Therapeutics、 Millennium Pharmaceuticals 及其子公司担任过高级职位。
Hugh M. Cole,Prior to joining Jounce in August 2017 Mr. Cole served as chief business officer for ARIAD Pharmaceuticals, Inc., an oncology company, from March 2014 to June 2017 where he led numerous business development transactions. Previously, Mr. Cole served as senior vice president, strategic planning and program management at Shire plc, a global biopharmaceutical company, from 2007 to March 2014. At Shire, Mr. Cole's responsibilities included the global development strategy and commercialization of the rare disease drug Firazyr. Earlier in his career, Mr. Cole was vice president, corporate development for Oscient Pharmaceuticals, Inc. and served as senior director, business development and strategy at Millennium Pharmaceuticals, Inc. Mr. Cole earned his M.B.A. in health care management and finance at the Wharton School of Business and his A.B. in chemistry from Harvard University.